Skip to main content
Mabion S.A. logo

Mabion S.A. — Investor Relations & Filings

Ticker · MAB ISIN · PLMBION00016 LEI · 259400KG5JVQPPZL6X53 WAR Manufacturing
Open in API
Filings indexed 1,002 across all filing types
Latest filing 2022-09-29 Interim / Quarterly Rep…
Country PL Poland
Listing WAR MAB

About Mabion S.A.

https://www.mabion.eu/en/

Mabion S.A. is an integrated Contract Development and Manufacturing Organization (CDMO) that provides end-to-end services for the development and manufacturing of protein-based biotherapeutics. The company specializes in monoclonal antibodies and biosimilars, offering a complete workflow from cell line development and banking to process optimization and large-scale GMP manufacturing. Core competencies include upstream processing using mammalian cell cultures, downstream purification involving chromatography and viral clearance, and technology transfer for scale-up. Mabion partners with pharmaceutical and biotechnology companies to support both clinical and commercial supply, streamlining the path from gene to final drug product.

Recent filings

Filing Released Lang Actions
Mabion MSSF_1H2022
Interim / Quarterly Report Classification · 100% confidence The document is a 'Śródroczne skrócone sprawozdanie finansowe' (Interim condensed financial statement) for MABION S.A. for the 6-month period ending June 30, 2022. It contains detailed financial statements, including the Statement of Comprehensive Income, Statement of Financial Position, and Statement of Cash Flows. It is not an announcement or a summary, but the actual financial report for an interim period, fitting the definition of an Interim/Quarterly Report (IR). H1 2022
2022-09-29 Polish
Rozszerzenie i wydłużenie współpracy z Novavax,Inc. - wariant Omicron - Content (PL)
M&A Activity Classification · 99% confidence The document is written in Polish and discusses an amendment ('aneks') to a Master Contract Manufacturing Agreement ('Umowa') between Mabion S.A. and Novavax regarding the commercial production of a COVID-19 vaccine antigen. It details changes to the contract duration (extended to 2026), payment terms (Manufacturing Slot Fee, per batch payment), and future production schedules, including the potential production of an Omicron variant antigen. This type of announcement, detailing significant changes to a major commercial contract, financing terms, or operational agreements, fits best under 'Capital/Financing Update' (CAP) or potentially 'Regulatory Filings' (RNS) if it were a mandatory disclosure without a better fit. However, since it directly concerns the financial structure and future revenue streams derived from a major contract modification, CAP is the most appropriate classification among the specific options, as it relates to capital/financing activities (contract value, payment structure). Given the context of a formal update on a significant business agreement, it is not an ER, IR, or 10-K. It is a specific business/financial update, making CAP the best fit over the general RNS.
2022-09-23 Polish
Zmiana terminu publikacji raportu za I półrocze 2022 roku - Content (PL)
Report Publication Announcement Classification · 98% confidence The document text is very short (339 characters) and explicitly states that the company management ('Zarząd Mabion S.A.') is informing the public about a *change in the date* for releasing the report for the first half of 2022 ('raportu za I półrocze 2022 roku'). It announces *when* the report will be published (September 29, 2022), rather than containing the report itself. This fits the definition of announcing the publication of a report, which corresponds to the Report Publication Announcement (RPA) code. It is not the Interim Report (IR) itself.
2022-09-19 Polish
Przyznanie akcji i podwyższenie kapitału zakładowego Spółki w ramach warunkowego podwyższenia kapitału zakładowego - Content (PL)
Share Issue/Capital Change Classification · 98% confidence The document explicitly discusses the issuance of new shares (500 common shares of series S) resulting from the exercise of subscription warrants under a Motivational Program. It details the resulting increase in the company's share capital ('podwyższenie kapitału zakładowego Spółki') and provides a full breakdown of the new total share structure. This content directly relates to changes in the company's capital structure and share issuance, fitting the definition of 'Capital/Financing Update' (CAP) or potentially 'Share Issue/Capital Change' (SHA). Since the core event is the issuance of shares following a capital program, SHA is the most precise fit, as it covers new share issues and capital changes. The document is a formal announcement detailing the mechanics and resulting capital figures.
2022-08-30 Polish
Oświadczenie Krajowego Depozytu Papierów Wartościowych S.A. w sprawie rejestracji akcji serii S Spółki - Content (PL)
Share Issue/Capital Change Classification · 95% confidence The document text, written in Polish, discusses the National Securities Depository (KDPW) registering 500 common bearer shares (series S) following the exercise of subscription warrants. It explicitly mentions the execution of rights to subscribe for these shares based on a resolution from the General Meeting concerning the issuance of shares to implement a Motivational Program. This action directly relates to changes in the company's capital structure (issuance of new shares following warrant exercise). This fits best under the 'Capital/Financing Update' category, which covers fundraising, financing activities, or capital structure changes.
2022-08-24 Polish
Podsumowanie subskrypcji akcji zwykłych na okaziciela serii S Spółki przeprowadzonej w ramach realizacji Programu Motywacyjnego za rok 2021 - Content (PL)
Share Issue/Capital Change Classification · 98% confidence The document details the completion of a subscription for Series S ordinary shares issued as part of a Motivational Program, involving the exercise of rights from Series B subscription warrants. It explicitly discusses the subscription process, number of shares subscribed (500), subscription price (0.10 PLN), total value (50 PLN), and the number of participants (9 people). This content directly relates to changes in the company's capital structure resulting from the issuance of new shares, which aligns perfectly with the definition of 'Share Issue/Capital Change' (SHA). It is not a general earnings release (ER), an interim report (IR), or a general regulatory announcement (RNS), but a specific report on a capital transaction.
2022-08-08 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.